Cargando…
A 2-Dose AERAS-402 Regimen Boosts CD8(+) Polyfunctionality in HIV-Negative, BCG-Vaccinated Recipients
Despite the widespread use of BCG, tuberculosis (TB) remains a global threat. Existing vaccine candidates in clinical trials are designed to replace or boost BCG which does not provide satisfying long-term protection. AERAS-402 is a replication-deficient Ad35 vaccine encoding a fusion protein of the...
Autores principales: | Sivakumaran, Dhanasekaran, Blatner, Gretta, Bakken, Rasmus, Hokey, David, Ritz, Christian, Jenum, Synne, Grewal, Harleen M. S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231292/ https://www.ncbi.nlm.nih.gov/pubmed/34177914 http://dx.doi.org/10.3389/fimmu.2021.673532 |
Ejemplares similares
-
Adenovirally-Induced Polyfunctional T Cells Do Not Necessarily Recognize the Infected Target: Lessons from a Phase I Trial of the AERAS-402 Vaccine
por: Nyendak, Melissa, et al.
Publicado: (2016) -
Added Value of IP-10 as a Read-Out of Mycobacterium tuberculosis: Specific Immunity in Young Children
por: Jenum, Synne, et al.
Publicado: (2016) -
Improving Assignments for Therapeutic and Prophylactic Treatment Within TB Households. A Potential for Immuno-Diagnosis?
por: Sivakumaran, Dhanasekaran, et al.
Publicado: (2022) -
A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults
por: Sheehan, Sharon, et al.
Publicado: (2015) -
Host blood-based biosignatures for subclinical TB and incipient TB: A prospective study of adult TB household contacts in Southern India
por: Sivakumaran, Dhanasekaran, et al.
Publicado: (2023)